UBS US Biotech: Alice Nettleton Publishes Inaugural Report on US SMID-Cap Biotechnology
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
UBS analyst Alice Nettleton initiates coverage of US small- and mid-cap (SMID) biotech, emphasizing the sector's high-risk, high-reward profile, with volatility often driven by binary clinical events. Combining scientific and commercial perspectives, she assesses Monte Rosa Therapeutics, Mineralys and Tectonic Therapeutic, mapping key catalyst timelines and twelve-month risk/reward scenarios, and urges caution when evaluating the space. Monte Rosa's MRT-8102 is differentiated in inflammation despite a -34% year-to-date share price decline after ZEUS data; catalysts include full ZEUS data in November 2026, MRT-2359 and MRT-6160 data around year-end 2026, and the ARTEMIS readout in 1H27. Mineralys's Lorundrostat has a positive approval outlook with a PDUFA date of December 22, 2026, though its commercial ramp may only match expectations (shares -36% YTD); AstraZeneca's Baxfendy data in CKD and primary aldosteronism is expected in 2H27. Tectonic's TX45 in PH-HFpEF remains uncertain, with the APEX readout in 1Q27; TX100 data is due October 2026. Ratings: Monte Rosa (GLUE) Buy, $19 target; Mineralys (MLYS) Neutral, $29; Tectonic (TECX) Neutral, $26. Spyre Therapeutics is unrated (last price $85.69; target $120.00).
Key exhibits
Exhibit 1
Exhibit 2
Exhibit 3
Exhibit 4
